Company Description

Shire-NPS Pharma, a Takeda company, have worldwide rights to develop and sell teduglutide, a treatment for a rare condition called short bowel syndrome sold in Europe as Revestive and in the United States as Gattex, and for an osteoporosis drug sold in Europe under the brand name Preotact.